University of Minnesota
This is a two-arm, open-label, randomized, phase 1, controlled clinical trial intended to evaluate the safety and immunologic response to the experimental vaccine H1ssF (H1 stabilized stem ferritin nanoparticle) and the seasonal flu vaccine Flucelvax.
Inclusion Criteria: * Adults aged 18-70 years inclusive. * Previous influenza immunization status: 1. MN participants must have received at least 3 licensed seasonal flu vaccine doses over the past 5 years (fall or winter of 2021-2025). 2. MN participants should have a gap of at least 6 months between their last seasonal flu vaccine and study enrollment. 3. Uganda participants must have no prior exposure to any flu vaccine. * The participant is able and willing to provide informed consent. * Medical chart review and medical history without clinically significant findings or concerns. *…
Experimental influenza vaccine
Licensed influenza vaccine
Arctuva estimate
Verify or correct the compensation shown for this listing.